Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) Position Increased by XTX Topco Ltd

Key Points

• XTX Topco Ltd increased its stake in Centessa Pharmaceuticals by 81.0%, acquiring an additional 18,377 shares during the first quarter, bringing its total holdings to 41,057 shares valued at approximately $590,000.
• Insider Arjun Goyal significantly boosted his position by acquiring 417,646 shares at an average cost of $12.73 per share, indicating a 929.36% increase in his holdings.
• Analysts have a consensus rating of "Moderate Buy" for Centessa Pharmaceuticals, with price targets ranging from $6.00 to $35.00, reflecting optimism about the company's future performance.

XTX Topco Ltd grew its position in Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA - Free Report) by 81.0% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 41,057 shares of the company's stock after buying an additional 18,377 shares during the quarter. XTX Topco Ltd's holdings in Centessa Pharmaceuticals were worth $590,000 at the end of the most recent quarter.

A number of other hedge funds have also made changes to their positions in the company. Windmill Hill Asset Management Ltd acquired a new stake in shares of Centessa Pharmaceuticals during the first quarter valued at $1,696,000. Wildcat Capital Management LLC acquired a new position in Centessa Pharmaceuticals in the 1st quarter valued at about $4,053,000. Cerity Partners LLC purchased a new position in Centessa Pharmaceuticals in the 1st quarter valued at about $471,000. Bank of New York Mellon Corp acquired a new stake in shares of Centessa Pharmaceuticals during the 1st quarter worth about $147,000. Finally, HighMark Wealth Management LLC grew its holdings in shares of Centessa Pharmaceuticals by 41.9% during the first quarter. HighMark Wealth Management LLC now owns 235,785 shares of the company's stock worth $3,391,000 after buying an additional 69,650 shares in the last quarter. Hedge funds and other institutional investors own 82.01% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on CNTA shares. Wall Street Zen upgraded Centessa Pharmaceuticals from a "sell" rating to a "hold" rating in a research note on Thursday, May 22nd. Needham & Company LLC began coverage on shares of Centessa Pharmaceuticals in a report on Wednesday, May 28th. They set a "buy" rating and a $35.00 price objective on the stock. Truist Financial started coverage on shares of Centessa Pharmaceuticals in a report on Monday, July 21st. They issued a "buy" rating and a $30.00 target price for the company. Oppenheimer initiated coverage on shares of Centessa Pharmaceuticals in a research note on Thursday, May 8th. They set an "outperform" rating and a $6.00 price target on the stock. Finally, Chardan Capital reissued a "buy" rating and set a $30.00 price objective on shares of Centessa Pharmaceuticals in a research note on Wednesday, July 30th. One analyst has rated the stock with a hold rating and eleven have assigned a buy rating to the company. According to data from MarketBeat.com, Centessa Pharmaceuticals has a consensus rating of "Moderate Buy" and a consensus target price of $28.10.

Insider Transactions at Centessa Pharmaceuticals

In other news, insider Gregory M. Weinhoff sold 10,000 shares of Centessa Pharmaceuticals stock in a transaction that occurred on Wednesday, June 25th. The shares were sold at an average price of $13.86, for a total transaction of $138,600.00. Following the sale, the insider owned 122,279 shares in the company, valued at $1,694,786.94. This trade represents a 7.56% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, General Counsel Iqbal J. Hussain sold 12,000 shares of the firm's stock in a transaction on Tuesday, June 24th. The shares were sold at an average price of $14.02, for a total transaction of $168,240.00. Following the sale, the general counsel directly owned 105,386 shares of the company's stock, valued at approximately $1,477,511.72. The trade was a 10.22% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 230,322 shares of company stock worth $3,196,684 over the last 90 days. 7.09% of the stock is owned by corporate insiders.

Centessa Pharmaceuticals Trading Down 0.9%

Shares of Centessa Pharmaceuticals stock traded down $0.16 during trading hours on Friday, hitting $17.02. The company's stock had a trading volume of 557,955 shares, compared to its average volume of 1,186,054. The company has a quick ratio of 14.37, a current ratio of 14.37 and a debt-to-equity ratio of 0.28. The company has a market capitalization of $2.27 billion, a PE ratio of -9.40 and a beta of 1.48. The business has a fifty day moving average of $14.29 and a 200 day moving average of $14.48. Centessa Pharmaceuticals PLC Sponsored ADR has a 1-year low of $9.60 and a 1-year high of $19.09.

Centessa Pharmaceuticals (NASDAQ:CNTA - Get Free Report) last issued its earnings results on Monday, May 12th. The company reported ($0.20) earnings per share for the quarter, topping the consensus estimate of ($0.35) by $0.15. As a group, equities analysts forecast that Centessa Pharmaceuticals PLC Sponsored ADR will post -1.6 EPS for the current year.

Centessa Pharmaceuticals Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.